Netherlands Pharmacovigilance Centre, Lareb, is a network organisation and has close contacts both on a national and international basis.
Lareb collects and analyses reports of suspected adverse drug reactions reported by health care professionals, patients and market authorisation holders. Lareb informs both government and health professionals about important new signals. Moreover, Lareb tries to increase health professionals’ involvement in pharmacovigilance, so they will be motivated to report adverse drug reactions in daily practice. Each year Lareb receives about 4500 reports of adverse drug reactions. In 20% of these reports, a serious adverse drug reaction is reported. Approximately 30 articles are published annually in national and international journals.
Note: This is an important resource for patients, their families and all care givers.